NeuroSense Therapeutics L... (NRSNW)
0.26
0.06 (32.79%)
At close: Apr 17, 2025, 12:47 PM
0.26
0.00%
After-hours: Apr 17, 2025, 04:00 PM EDT
32.79% (1D)
| Bid | 0.22 |
| Market Cap | 6.24M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.21M |
| EPS (ttm) | -0.935 |
| PE Ratio (ttm) | -0.28 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.3 |
| Volume | 2,210 |
| Avg. Volume (20D) | 8,966.431 |
| Open | 0.20 |
| Previous Close | 0.20 |
| Day's Range | 0.20 - 0.26 |
| 52-Week Range | 0.20 - 0.26 |
| Beta | 1.34 |
About NRSNW
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's dise...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 17
Stock Exchange NASDAQ
Ticker Symbol NRSNW
Website https://www.neurosense-tx.com